Citigroup Downgrades Bruker to Neutral, PT Decreased to $38 from $40

Citigroup Downgrades Bruker to Neutral, PT Decreased to $38 from $40

Citigroup has downgraded Bruker Corporation (NASDAQ: BRKR) to a "Neutral" rating and reduced its price target (PT) from $40 to $38. This move comes after the company's recent earnings report, which showed a decline in revenue and earnings per share (EPS) compared to forecasts. The stock price reacted negatively, falling by 15.11% in pre-market trading following the earnings announcement.

Bruker Corporation reported an EPS of $0.32 for the second quarter of 2025, which was 23.81% below the expected $0.42. Revenue came in at $797.4 million, slightly below the forecasted $812.81 million, resulting in a 1.9% revenue miss. Despite the challenges, Bruker maintains a strong financial health score and continues to hold strong positions in key markets such as post-genomic tools and microbiology diagnostics.

The company also announced a cost-saving initiative targeting €100-120 million in annual reductions. Bruker remains optimistic about a partial market recovery in 2026. The stock's current price of $34.25 is near its 52-week low of $32.20, indicating investor concern over the company's performance and future prospects.

The downgrade and PT reduction by Citigroup reflect the broader market sentiment towards Bruker, which has seen a significant decrease in analyst ratings and institutional holdings. TD Asset Management Inc. reduced its holdings in Bruker by 43.4% during the first quarter, selling 597,406 shares and owning approximately 0.51% of the company valued at $32.5 million [1].

References:
[1] https://www.marketbeat.com/instant-alerts/filing-td-asset-management-inc-reduces-position-in-bruker-corporation-nasdaqbrkr-2025-07-29/
[2] https://www.investing.com/news/transcripts/earnings-call-transcript-bruker-q2-2025-misses-forecasts-stock-drops-93CH-4168074